Search research articles
Contact Us
Filters
Showing results (51-60 of 106) with videos related to
Page
of 11
Sort By:
Breast Cancer Research and Treatment
|
February 4, 2014
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Andrea Decensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2019
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
Olivia Pagani, Prudence A Francis, Gini F Fleming, et al.
Breast Cancer Research and Treatment
|
March 29, 2018
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00
Elisabetta Munzone, Kathryn P Gray, Caterina Fumagalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
Meredith M Regan, Prudence A Francis, Olivia Pagani, et al.
Clinical Breast Cancer
|
July 25, 2008
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
Irene L Wapnir, Stefan Aebi, Charles E Geyer, et al.
Breast Cancer Research and Treatment
|
October 28, 2008
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Olivia Pagani, Shari Gelber, Edda Simoncini, et al.
Breast Cancer Research and Treatment
|
November 7, 2020
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Manuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Marco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
JCO Precision Oncology
|
January 24, 2025
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials
Stephen J Luen, Lauren C Brown, Courtney T van Geelen, et al.
The Lancet. Oncology
|
September 10, 2018
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
Viviana Galimberti, Bernard F Cole, Giuseppe Viale, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 106) with videos related to
Sort By:
Page
of 11
Breast Cancer Research and Treatment
|
February 4, 2014
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences
Andrea Decensi, Zhuoxin Sun, Aliana Guerrieri-Gonzaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2019
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
Olivia Pagani, Prudence A Francis, Gini F Fleming, et al.
Breast Cancer Research and Treatment
|
March 29, 2018
Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00
Elisabetta Munzone, Kathryn P Gray, Caterina Fumagalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
Meredith M Regan, Prudence A Francis, Olivia Pagani, et al.
Clinical Breast Cancer
|
July 25, 2008
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
Irene L Wapnir, Stefan Aebi, Charles E Geyer, et al.
Breast Cancer Research and Treatment
|
October 28, 2008
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Olivia Pagani, Shari Gelber, Edda Simoncini, et al.
Breast Cancer Research and Treatment
|
November 7, 2020
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Manuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Marco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
JCO Precision Oncology
|
January 24, 2025
Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2-Low, Hormone Receptor-Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials
Stephen J Luen, Lauren C Brown, Courtney T van Geelen, et al.
The Lancet. Oncology
|
September 10, 2018
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
Viviana Galimberti, Bernard F Cole, Giuseppe Viale, et al.
Page
of 11